Theravance Biopharma Halts Ampreloxetine Program Following Phase 3 Study Failure
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 hours ago
0mins
Should l Buy TBPH?
Source: PRnewswire
- Clinical Trial Setback: Theravance Biopharma's CYPRESS study failed to meet its primary endpoint, leading to the termination of the ampreloxetine program, which disappointed both patients and employees and significantly impacts the company's future R&D direction.
- Accelerated Strategic Review: The Strategic Review Committee of the Board is expediting its evaluation of various value-maximizing strategic alternatives, including a potential sale of the company, in response to the ampreloxetine program's failure and to enhance shareholder value.
- Organizational Restructuring: The company plans to undergo an organizational restructuring that will cut approximately 50% of its workforce and completely wind down the R&D function, which is expected to reduce operating expenses by about 60%, allowing a sharper focus on the commercialization of YUPELRI®.
- Cash Flow Projections: Following the restructuring, Theravance Biopharma anticipates generating approximately $60 to $70 million in annualized cash flow starting in Q3 2026, providing a stable financial foundation to support future operations and growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TBPH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TBPH
Wall Street analysts forecast TBPH stock price to rise
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 18.950
Low
13.00
Averages
28.40
High
42.00
Current: 18.950
Low
13.00
Averages
28.40
High
42.00
About TBPH
Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development and commercialization of medicines for the specialty respiratory and neurologic diseases. The Company operates through a single segment, namely, development and commercialization of human therapeutics. Its product, YUPELRI (revefenacin) inhalation solution, is a nebulized long-acting muscarinic antagonist used for the treatment of patients with chronic obstructive pulmonary disease (COPD). COPD is a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in the lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath, and others. Its Ampreloxetine, is a late-stage investigational norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension in patients with Multiple System Atrophy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Theravance Biopharma Cuts Workforce by 50% Amid Phase 3 Trial Failure
- Trial Failure: Theravance Biopharma's CYPRESS study failed to achieve statistical significance on its primary endpoint, leading to the decision to wind down the program, which is expected to have a significant negative impact on future revenues.
- Workforce and Cost Cuts: The company announced a 50% reduction in its workforce and plans to cut operating expenses by about 60%, anticipating one-time cash severance expenses of $5 million to $7 million over the next two quarters.
- Sales Outlook: Despite the challenges, Theravance expects global net sales to reach at least $3.51 billion in 2026, indicating the potential of its product YUPELRI in treating chronic obstructive pulmonary disease.
- Stock Reaction: Theravance's shares plunged nearly 30% following the announcement, breaking below the 200-day moving average for the first time, reflecting the market's pessimism regarding the company's future prospects.
See More
THERAVANCE BIOPHARMA INC: PHASE 3 CYPRESS STUDY FAILED TO ACHIEVE PRIMARY OBJECTIVE
- Study Overview: The Phase 3 study conducted by The Ravanace Biopharma did not achieve its primary endpoint.
- Implications: The failure to meet the primary endpoint may impact the future development and approval of the drug in question.
See More
Theravance Biopharma Announces Phase 3 CYPRESS Study Failed to Achieve Primary Endpoint; Board Initiates Strategic Review and Implements Cost-Cutting Measures
Study Results: The Phase 3 study conducted by the company did not meet its primary endpoint, indicating that the expected outcomes were not achieved.
Strategic Review: The board has accelerated a strategic review process in light of the study results, suggesting a reassessment of the company's direction.
Cost Reduction Actions: The company has announced actions aimed at reducing costs, likely as a response to the disappointing study results and the need for financial efficiency.
Future Implications: The outcomes of the study and subsequent strategic decisions may impact the company's future projects and overall market position.
See More
U.S. Stocks Decline Amid Ongoing Iran-U.S. Conflict
- Dow Jones Plummets: The Dow Jones index fell over 900 points on Tuesday, down 1.85% to 48,002.16, reflecting market sensitivity to geopolitical risks amid the ongoing Iran-U.S. conflict.
- NASDAQ and S&P 500 Decline: The NASDAQ dipped 1.80% to 22,338.43, while the S&P 500 dropped 1.65% to 6,768.35, indicating investor concerns about market outlook.
- Commodity Market Fluctuations: Oil prices surged 8.4% to $77.23 per barrel, driven by supply disruption fears, while gold and silver fell 3.3% and 8.2%, respectively, suggesting a decrease in safe-haven demand.
- European Markets Decline: The eurozone's STOXX 600 index fell 3.2%, and Spain's IBEX 35 index dropped 4.8%, reflecting global market reactions to the downturn in U.S. stocks, which may impact investor confidence.
See More
Theravance Biopharma Halts Clinical Program for Ampreloxetine
- Clinical Trial Setback: Theravance Biopharma announced the halt of its clinical program for ampreloxetine due to the Phase 3 CYPRESS study failing to meet its primary endpoint, resulting in a trading halt for the company's shares and negatively impacting investor confidence.
- Cost Reduction Initiative: The company is implementing a cost reduction program that will involve layoffs of approximately 50% of its workforce, allowing it to focus on its FDA-approved COPD treatment, Yupelri, and achieve nearly a 60% reduction in operating expenses this year.
- Future Cash Flow Projections: Theravance projects an annualized cash flow of $60 million to $70 million starting in Q3 2026 from Yupelri sales, indicating potential profitability post-restructuring despite current setbacks.
- Market Reaction: The failure of the clinical trial and the layoff plan may exert further pressure on Theravance's stock price, prompting investors to closely monitor how the company adjusts its strategy to navigate these challenges.
See More
Theravance Biopharma Halts Ampreloxetine Program Following Phase 3 Study Failure
- Clinical Trial Setback: Theravance Biopharma's CYPRESS study failed to meet its primary endpoint, leading to the termination of the ampreloxetine program, which disappointed both patients and employees and significantly impacts the company's future R&D direction.
- Accelerated Strategic Review: The Strategic Review Committee of the Board is expediting its evaluation of various value-maximizing strategic alternatives, including a potential sale of the company, in response to the ampreloxetine program's failure and to enhance shareholder value.
- Organizational Restructuring: The company plans to undergo an organizational restructuring that will cut approximately 50% of its workforce and completely wind down the R&D function, which is expected to reduce operating expenses by about 60%, allowing a sharper focus on the commercialization of YUPELRI®.
- Cash Flow Projections: Following the restructuring, Theravance Biopharma anticipates generating approximately $60 to $70 million in annualized cash flow starting in Q3 2026, providing a stable financial foundation to support future operations and growth.
See More
Theravance Biopharma Cuts Workforce by 50% Amid Phase 3 Trial Failure
- Trial Failure: Theravance Biopharma's CYPRESS study failed to achieve statistical significance on its primary endpoint, leading to the decision to wind down the program, which is expected to have a significant negative impact on future revenues.
- Workforce and Cost Cuts: The company announced a 50% reduction in its workforce and plans to cut operating expenses by about 60%, anticipating one-time cash severance expenses of $5 million to $7 million over the next two quarters.
- Sales Outlook: Despite the challenges, Theravance expects global net sales to reach at least $3.51 billion in 2026, indicating the potential of its product YUPELRI in treating chronic obstructive pulmonary disease.
- Stock Reaction: Theravance's shares plunged nearly 30% following the announcement, breaking below the 200-day moving average for the first time, reflecting the market's pessimism regarding the company's future prospects.
See More
THERAVANCE BIOPHARMA INC: PHASE 3 CYPRESS STUDY FAILED TO ACHIEVE PRIMARY OBJECTIVE
- Study Overview: The Phase 3 study conducted by The Ravanace Biopharma did not achieve its primary endpoint.
- Implications: The failure to meet the primary endpoint may impact the future development and approval of the drug in question.
See More
Theravance Biopharma Announces Phase 3 CYPRESS Study Failed to Achieve Primary Endpoint; Board Initiates Strategic Review and Implements Cost-Cutting Measures
Study Results: The Phase 3 study conducted by the company did not meet its primary endpoint, indicating that the expected outcomes were not achieved.
Strategic Review: The board has accelerated a strategic review process in light of the study results, suggesting a reassessment of the company's direction.
Cost Reduction Actions: The company has announced actions aimed at reducing costs, likely as a response to the disappointing study results and the need for financial efficiency.
Future Implications: The outcomes of the study and subsequent strategic decisions may impact the company's future projects and overall market position.
See More
U.S. Stocks Decline Amid Ongoing Iran-U.S. Conflict
- Dow Jones Plummets: The Dow Jones index fell over 900 points on Tuesday, down 1.85% to 48,002.16, reflecting market sensitivity to geopolitical risks amid the ongoing Iran-U.S. conflict.
- NASDAQ and S&P 500 Decline: The NASDAQ dipped 1.80% to 22,338.43, while the S&P 500 dropped 1.65% to 6,768.35, indicating investor concerns about market outlook.
- Commodity Market Fluctuations: Oil prices surged 8.4% to $77.23 per barrel, driven by supply disruption fears, while gold and silver fell 3.3% and 8.2%, respectively, suggesting a decrease in safe-haven demand.
- European Markets Decline: The eurozone's STOXX 600 index fell 3.2%, and Spain's IBEX 35 index dropped 4.8%, reflecting global market reactions to the downturn in U.S. stocks, which may impact investor confidence.
See More
Theravance Biopharma Halts Clinical Program for Ampreloxetine
- Clinical Trial Setback: Theravance Biopharma announced the halt of its clinical program for ampreloxetine due to the Phase 3 CYPRESS study failing to meet its primary endpoint, resulting in a trading halt for the company's shares and negatively impacting investor confidence.
- Cost Reduction Initiative: The company is implementing a cost reduction program that will involve layoffs of approximately 50% of its workforce, allowing it to focus on its FDA-approved COPD treatment, Yupelri, and achieve nearly a 60% reduction in operating expenses this year.
- Future Cash Flow Projections: Theravance projects an annualized cash flow of $60 million to $70 million starting in Q3 2026 from Yupelri sales, indicating potential profitability post-restructuring despite current setbacks.
- Market Reaction: The failure of the clinical trial and the layoff plan may exert further pressure on Theravance's stock price, prompting investors to closely monitor how the company adjusts its strategy to navigate these challenges.
See More
Theravance Biopharma Halts Ampreloxetine Program Following Phase 3 Study Failure
- Clinical Trial Setback: Theravance Biopharma's CYPRESS study failed to meet its primary endpoint, leading to the termination of the ampreloxetine program, which disappointed both patients and employees and significantly impacts the company's future R&D direction.
- Accelerated Strategic Review: The Strategic Review Committee of the Board is expediting its evaluation of various value-maximizing strategic alternatives, including a potential sale of the company, in response to the ampreloxetine program's failure and to enhance shareholder value.
- Organizational Restructuring: The company plans to undergo an organizational restructuring that will cut approximately 50% of its workforce and completely wind down the R&D function, which is expected to reduce operating expenses by about 60%, allowing a sharper focus on the commercialization of YUPELRI®.
- Cash Flow Projections: Following the restructuring, Theravance Biopharma anticipates generating approximately $60 to $70 million in annualized cash flow starting in Q3 2026, providing a stable financial foundation to support future operations and growth.
See More
